What Happens When You Stop GLP-1 Medication
Even traditionally resilient categories such as fresh meat and deli are seeing softer demand, not because consumers are avoiding protein, but because they are simply eating less overall
View all Amino BCAA Best Sellers Beta Alalnine Caffeine Carbohydrates Casein CLA Collagen Creatine Diuretic Drinks EAA Egg Protein Electrolytes Fat Burner Fish Oils Glutamine Glycerol Greens Heart Health HMB Immune Support Insulin Support Joint Support L-Carnitine Liver Support Male Enhancement Mass Gainers Meal Replacement Multi-Vitamin Muscle Builders Nitric Oxide Non-Stim Pre-Workout Nootropic PCT Plant Protein Pre-Workout Proteins Sleep Aid Snacks and Bars Testbooster Yohimbine ZMA Our Brands New Arrivals Promos Bulk order form Catalog Sign up to our email blast
Injections are best administered with an auto-injector, but can be injected using the same syringe that diabetics use
Predicted coverage changes post-approval: Based on the coverage expansion pattern when Wegovy gained FDA approval for obesity in 2021, we expect: 60-70% of large-employer commercial plans to cover GLP-1s for NASH within 6 months of FDA approval 30-40% of marketplace plans to add coverage within 12 months Medicare Part D to cover for NASH (but not for obesity, due to the statutory weight-loss drug exclusion) Medicaid coverage to remain state-specific, with 15-20 states adding NASH coverage within 18 months Prior authorization will still be required, but approval rates will flip from 25% (current off-label rate) to 70-80% (typical for newly approved indications)
Labelling: Clearly label the opened container with the date of opening and any other relevant information, such as the expiration date or the intended use of the water
